drugset
drugset / Trial / NCT05436561

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

NCT05436561 ↗

Phase 2 Recruiting 61 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.

Timeline

Start
2022-06-01
Primary completion
2026-12-01
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Background Busulfan Small molecule 6.4 mg/kg —
Background Fludarabine Small molecule 150 mg/m2 —
Background Melphalan Small molecule 100 mg/m2 —

Indications

No indication recorded.